Ewelina Weglarz-Tomczak (UvA): Lysosomal protease inhibitors for Alzheimer’s
Ewelina Weglarz-Tomczak (UvA): Novel lysosomal protease inhibitors for the treatment of Alzheimer’s disease
Highly specified proteases are the key regulators in the molecular mechanism of neurodegeneration in Alzheimer’s disease. AI-powered technology developed by NatInLab has led to the discovery of how those proteases are controlled in the human organism. Based on this knowledge, developing novel, highly effective and safe inhibitors of these proteases is possible. The project aims to deliver new agents against Alzheimer’s and possibly other neurodegenerative diseases as the next step. The novel drugs are expected to be curative and show minimal side effects.
Explore other Cases:
Marjon van Rijn (HvA): Journey to the end of life
Marjon van Rijn (HvA): Journey to the end of life Research indicates that healthcare professionals often struggle to initiate conversations about the wishes and preferences for care and treatment at the end of life with older people. A partial solution lies in providing training for these discussions within a safe learning environment by way of […]
Georges Janssens (Amsterdam UMC): My Health Buddy
Georges Janssens (Amsterdam UMC): MyHeBu (My Health Buddy), a wearable device-based and AI-powered digital twin to track your health and aging. Many people are tracking all of their health data using wearable devices, but it’s not really giving them answers to simple questions like: ‘How often should I exercise?’, or ‘Is my high protein diet […]
Zeliha Guler (Amsterdam UMC): Novel wound-healing implant
Zeliha Guler (Amsterdam UMC): Development of a novel wound-healing implant with localized estradiol delivery One out of four women is under risk for prolapse, and it increases up to 60% by age or giving birth. For the correction of prolapse permanent implants are being used, but they may cause clinical complications in the long term. […]